

Digital Biomarkers Market by Type (Physiological, Vocal, Idiosyncratic), Therapy [Cardio, Onco (Lung, Breast Cancer), Mental Health, Neuro], Application [Clinical Research (Phase IV)], End User (Pharma & Biotech Companies, CROs) – Global Forecast to 2031

<https://marketpublishers.com/r/D5CD44047BA9EN.html>

Date: April 2026

Pages: 402

Price: US\$ 4,950.00 (Single User License)

ID: D5CD44047BA9EN

Abstracts

The global digital biomarkers market is projected to reach USD 17.73 billion by 2031, growing from USD 7.41 billion in 2026 at a CAGR of 19.1%. The digital biomarkers market is being driven by the rapid evolution of data-driven clinical trials and the growing trend of integrating digital health technology into clinical trials. Pharmaceutical and biotech companies are increasingly using digital biomarkers in various stages of clinical trials to enable continuous and objective patient monitoring, thus improving data quality and endpoint accuracy. This is a part of a larger trend towards more efficient and patient-centric clinical trials, in which data from real-world sources plays a crucial role in determining the effectiveness of a drug. At the same time, there is a growing trend toward more decentralized clinical trials, in which data is collected more frequently by using remote data collection technology such as wearable devices and sensor technology. This is a part of a larger trend towards more digital biomarker software technology in clinical trials.

“By type, the physiological biomarkers segment is expected to account for the largest market share of the digital biomarkers market during the forecast period.”

By type, the physiological biomarkers segment is expected to hold the largest share of the digital biomarkers market during the forecast period. This is mainly due to the widespread use of continuous physiological measures like heart rate, ECG, respiratory rate, and activity levels in various clinical research and patient care settings. Physiological biomarkers are scalable and are well validated, making them more

suitable for remote patient monitoring and chronic disease management. In addition, the growing trend of using software platforms and AI-based tools associated with wearable devices is further propelling their adoption, particularly in cardiovascular and metabolic conditions where continuous monitoring is critical in making clinical decisions. This is also evident from published research that states that physiological data streams like heart rate and activity levels are some of the most commonly used digital endpoints in clinical trials, mainly due to their objectivity and ability to provide high-frequency and real-world data. In addition, the move towards decentralized trials and RWE generation is also further solidifying their position in the field of digital biomarkers, as they allow for patient monitoring outside traditional clinical environments.

In June 2025, AliveCor, Inc. (US) partnered with the British Heart Foundation (UK), donating proceeds from its KardiaMobile 6L device to support cardiovascular research and promote the adoption of digital heart rhythm monitoring technologies. These examples further hint at the growing role of physiological digital biomarkers in advancing cardiac care and research.

“By end user, the hospitals & specialty clinics segment is expected to achieve the fastest growth during the forecast period.”

By end user, the hospitals & specialty clinics segment is expected to witness the highest growth in the digital biomarkers market over the forecast period. The growth in this segment can be attributed to the rising adoption of digital biomarkers in hospitals and specialty clinics for real-time patient monitoring. Digital biomarkers are being increasingly integrated into the workflows of hospitals and specialty clinics for data-driven decision-making. Hospitals and specialty clinics are adopting wearable-enabled platforms and artificial intelligence-based analytics solutions for continuously monitoring physiological, cognitive, and behavioral changes in patients. Digital biomarkers help hospitals and specialty clinics in continuously monitoring patient data in real-time, thus helping in the early detection of changes in patient health. Moreover, the rising trend of value-based care is fueling the adoption of remote monitoring solutions in hospitals and specialty clinics. The rising prevalence of chronic diseases such as cardiovascular diseases, neurological disorders, and diabetes is also contributing to the growth of the digital biomarkers market in hospitals and specialty clinics. The rising trend of health information technology, which allows for seamless integration of digital biomarker solutions into electronic health records, is also fueling the growth of the digital biomarkers market in hospitals and specialty clinics.

“Asia Pacific to witness the highest growth rate during the forecast period.”

The digital biomarkers market in Asia Pacific is growing rapidly, with the region witnessing high growth in the expansion of clinical research activities. The region is witnessing the incorporation of digital technologies into the healthcare infrastructure. Countries such as India, South Korea, Japan, and Australia are gaining importance as hubs for clinical research activities. Due to the improvement in the regulatory environment and the cost advantage, the pharmaceutical and biotech industries are increasingly using the Asia Pacific as a hub for conducting clinical research activities. As the pharmaceutical and biotech industries increasingly rely on digital technologies to conduct clinical research activities, the digital biomarkers market is growing rapidly.

Asia Pacific is witnessing the incorporation of digital technologies into the healthcare infrastructure. The region is witnessing the expansion of clinical research activities. In November 2025, Lunit Inc., a South Korean-based company, announced its collaboration with Labcorp to conduct research using digital pathology technology powered by artificial intelligence and expand access to imaging-based biomarkers for clinical and translational oncology research globally. Such developments indicate the potential of the region as a lucrative market for digital biomarkers.

The breakdown of primary participants is as follows:

By Company Type – Tier 1 Companies: 60%, Tier 2 Companies: 30%, and Tier 3 Companies: 10%

By Designation – C-level Executives: 30%, Director-level Personnel: 50%, and Other Designations: 20%

By Region – North America: 45%, Europe: 20%, Asia Pacific: 25%, Rest of the world: 10%

IXICO PLC (UK), Ametris, LLC (US), and Empatica, Inc. (US) are some of the key players in the digital biomarkers market. The study includes an in-depth competitive analysis of these key players, their company profiles, recent developments, and key market strategies.

Research Coverage:

This research report categorizes the digital biomarkers market by type (physiological

biomarkers, idiosyncratic biomarkers, cognitive biomarkers, vocal biomarkers, and other biomarkers), therapeutic area {cardiovascular [atherosclerotic cardiovascular disease (ASCVD)/secondary prevention, heart failure (HFrEF and HFpEF), hypertension, atrial fibrillation (AF)/stroke prevention, pulmonary hypertension, and structural heart disease/interventional cardiology], oncology (solid tumors, hematologic malignancies), diabetes, mental health & behavioral health, respiratory disorders, lifestyle & wellness improvement, neurology, musculoskeletal disorders/pain management, women's health & reproductive health, and other diseases}, application, [clinical research applications (phase II, phase III, phase IV) and clinical care applications], end user [pharmaceutical and biotechnology companies, contract research organizations (CROs), hospitals and specialty clinics, and others (including research institutes, etc.)] and region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa).

The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the digital biomarkers market. A detailed analysis of the key industry players has been done to provide insights into their business overview; solutions and services; contracts, partnerships, agreements, product & service launches, mergers & acquisitions; and recent developments associated with the digital biomarkers market. Competitive analysis of upcoming startups in the digital biomarkers market ecosystem is covered in this report.

Reasons to Buy this Report:

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the digital biomarkers market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.

The report provides insights into the following pointers:

Analysis of key drivers (Expansion of smartphones, wearables, and connected health ecosystems; expansion of decentralized and remote clinical trials; rising prevalence of chronic diseases requiring continuous monitoring; advancements in AI and digital health analytics) restraints (Data privacy and security concerns related to health data, limited digital literacy and technology access among

patients) opportunities (Increasing use of digital biomarkers in drug development and clinical trial endpoints, growth of precision medicine and personalized healthcare, emerging applications in neurological and mental health monitoring), challenges (Lack of standardized validation frameworks for digital biomarkers, regulatory uncertainty around digital endpoints and biomarker validation) influencing the growth of the digital biomarkers market

Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and product & service launches in the digital biomarkers market

Market Development: Comprehensive information about lucrative markets across varied regions

Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the digital biomarkers market

Competitive Assessment: In-depth assessment of market share, growth strategies, and service offerings of leading players, namely IXICO PLC (UK), Ametris, LLC (US), Empatica, Inc. (US), AliveCor, Inc. (US), CONNEQT Health (US), VivoSense (US), BioSensics (US), Lunit, Inc. (South Korea), among others, in the digital biomarkers market

Contents

1 INTRODUCTION

- 1.1 STUDY OBJECTIVES
- 1.2 MARKET DEFINITION
- 1.3 MARKET SCOPE
 - 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
 - 1.3.2 INCLUSIONS & EXCLUSIONS
 - 1.3.3 YEARS CONSIDERED
- 1.4 CURRENCY CONSIDERED
- 1.5 LIMITATIONS
- 1.6 STAKEHOLDERS

2 EXECUTIVE SUMMARY

- 2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS
- 2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS
- 2.3 DISRUPTIVE TRENDS SHAPING THE MARKET
- 2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS
- 2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST

3 PREMIUM INSIGHTS

- 3.1 DIGITAL BIOMARKERS MARKET OVERVIEW
- 3.2 DIGITAL BIOMARKERS MARKET, BY APPLICATION & REGION
- 3.3 DIGITAL BIOMARKERS MARKET: GEOGRAPHIC SNAPSHOT

4 MARKET OVERVIEW

- 4.1 INTRODUCTION
- 4.2 MARKET DYNAMICS
 - 4.2.1 DRIVERS
 - 4.2.1.1 Expansion of smartphones, wearables, and connected health ecosystems
 - 4.2.1.2 Expansion of decentralized and remote clinical trials
 - 4.2.1.3 Rising prevalence of chronic diseases that require continuous monitoring
 - 4.2.1.4 Advancements in AI and digital health analytics
 - 4.2.2 RESTRAINTS

4.2.2.1 Data privacy and cybersecurity concerns

4.2.2.2 Limited digital literacy and technology access among patients

4.2.3 OPPORTUNITIES

4.2.3.1 Increasing use in drug development and clinical trial endpoints

4.2.3.2 Growth of precision medicine and personalized healthcare

4.2.3.3 Emerging applications in neurological and mental health monitoring

4.2.4 CHALLENGES

4.2.4.1 Lack of standardized validation frameworks for digital biomarkers

4.2.4.2 Regulatory uncertainty around digital endpoints and biomarker validation

4.3 UNMET NEEDS AND WHITE SPACES

4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES

4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS

5 INDUSTRY TRENDS

5.1 PORTER'S FIVE FORCES ANALYSIS

5.1.1 BARGAINING POWER OF SUPPLIERS (MODERATE)

5.1.2 BARGAINING POWER OF BUYERS (HIGH)

5.1.3 THREAT OF SUBSTITUTES (MODERATE TO HIGH)

5.1.4 THREAT OF NEW ENTRANTS (MODERATE)

5.1.5 INTENSITY OF COMPETITIVE RIVALRY (HIGH)

5.2 MACROECONOMIC INDICATORS

5.2.1 INTRODUCTION

5.2.2 GDP TRENDS AND FORECAST

5.2.3 TRENDS IN GLOBAL HEALTHCARE IT INDUSTRY

5.3 SUPPLY CHAIN ANALYSIS

5.4 ECOSYSTEM ANALYSIS

5.5 PRICING ANALYSIS

5.5.1 INDICATIVE PRICE FOR DIGITAL BIOMARKERS, BY KEY PLAYER (2025)

5.5.2 INDICATIVE PRICE FOR DIGITAL BIOMARKERS, BY REGION (2025)

5.6 KEY CONFERENCES AND EVENTS, 2026–2027

5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS

5.8 INVESTMENT AND FUNDING SCENARIO

5.9 CASE STUDY ANALYSIS

5.10 IMPACT OF 2025 US TARIFF ON DIGITAL BIOMARKERS MARKET

5.10.1 INTRODUCTION

5.10.2 KEY TARIFF RATES

5.10.3 PRICE IMPACT ANALYSIS

5.10.4 IMPACT ON COUNTRY/REGION

5.10.4.1 US

5.10.4.2 Europe

5.10.4.3 Asia Pacific

5.10.5 IMPACT ON END USERS

5.10.5.1 Pharmaceutical and biotechnology companies

5.10.5.2 Contract research organizations

5.10.5.3 Hospitals and specialty clinics

5.10.5.4 Others (research institutes, etc.)

6 CUSTOMER LANDSCAPE & BUYER BEHAVIOR

6.1 INTRODUCTION

6.2 DECISION-MAKING PROCESS

6.3 KEY STAKEHOLDERS AND BUYING EVALUATION CRITERIA

6.3.1 KEY STAKEHOLDERS IN BUYING PROCESS

6.3.2 BUYING CRITERIA

6.4 ADOPTION BARRIERS & INTERNAL CHALLENGES

6.5 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES

6.5.1 UNMET NEEDS

6.5.2 END USER EXPECTATIONS

6.6 MARKET PROFITABILITY

7 REGULATORY LANDSCAPE

7.1 REGIONAL REGULATIONS AND COMPLIANCE

7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, & OTHER ORGANIZATIONS

7.1.2 REGULATORY FRAMEWORK

7.1.2.1 North America

7.1.2.2 Europe

7.1.2.3 Asia Pacific

7.1.2.4 Latin America

7.1.2.5 Middle East & Africa

7.1.3 INDUSTRY STANDARDS

8 STRATEGIC DISRUPTION THROUGH TECHNOLOGY, PATENTS, AND AI ADOPTION

8.1 KEY EMERGING TECHNOLOGIES

- 8.1.1 WEARABLE SENSOR TECHNOLOGIES
- 8.1.2 ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING ANALYTICS
- 8.1.3 MOBILE HEALTH (MHEALTH) PLATFORMS AND SMARTPHONE SENSORS
- 8.2 COMPLEMENTARY TECHNOLOGIES
 - 8.2.1 INTERNET OF MEDICAL THINGS (IOMT)
 - 8.2.2 TELEHEALTH AND REMOTE PATIENT MONITORING
- 8.3 ADJACENT TECHNOLOGIES
 - 8.3.1 DIGITAL THERAPEUTICS
 - 8.3.2 DIGITAL PATHOLOGY AND IMAGING AI
- 8.4 TECHNOLOGY/PRODUCT ROADMAP
- 8.5 PATENT ANALYSIS
 - 8.5.1 PATENT PUBLICATION TRENDS IN DIGITAL BIOMARKERS MARKET
 - 8.5.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
- 8.6 FUTURE APPLICATIONS
 - 8.6.1 AI-ENABLED INTELLIGENT SCREENING AND INTERPRETATION
 - 8.6.2 CONTINUOUS AND PREDICTIVE HEALTH MONITORING APPLICATIONS
 - 8.6.3 DECENTRALIZED, REMOTE, AND REAL-WORLD DATA ECOSYSTEMS
- 8.7 IMPACT OF AI/GEN AI ON DIGITAL BIOMARKERS MARKET
 - 8.7.1 INTRODUCTION
 - 8.7.2 MARKET POTENTIAL OF AI/GEN AI IN DIGITAL BIOMARKERS MARKET
 - 8.7.3 CASE STUDIES RELATED TO AI/GEN AI IMPLEMENTATION
 - 8.7.3.1 Early Alzheimer's detection using mobile-based cognitive assessment platforms
 - 8.7.4 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS
 - 8.7.4.1 Digital health market
 - 8.7.4.2 Remote patient monitoring market
 - 8.7.4.3 Telehealth & telemedicine market
 - 8.7.5 USER READINESS AND IMPACT ASSESSMENT
 - 8.7.5.1 User readiness
 - 8.7.5.1.1 User A: Pharmaceutical & biotechnology companies
 - 8.7.5.1.2 User B: Contract research organizations (CROs)
 - 8.7.5.2 Impact assessment
 - 8.7.5.2.1 User A: Pharmaceutical & biotechnology companies
 - 8.7.5.2.1.1 Implementation
 - 8.7.5.2.1.2 Impact
 - 8.7.5.2.2 User B: Contract research organizations
 - 8.7.5.2.2.1 Implementation
 - 8.7.5.2.2.2 Impact

9 DIGITAL BIOMARKERS MARKET, BY TYPE

9.1 INTRODUCTION

9.2 PHYSIOLOGICAL BIOMARKERS

9.2.1 SEGMENT LEADS MARKET ADOPTION THROUGH CLINICAL VALIDATION AND AI-DRIVEN ANALYTICS

9.3 IDIOSYNCRATIC BIOMARKERS

9.3.1 PRECISION MEDICINE DRIVEN THROUGH PERSONALIZED, INDIVIDUAL-LEVEL DATA INSIGHTS

9.4 COGNITIVE BIOMARKERS

9.4.1 ENABLE SCALABLE AND OBJECTIVE MEASUREMENT OF NEUROLOGICAL FUNCTION THROUGH ADVANCED ANALYTICS

9.5 VOCAL BIOMARKERS

9.5.1 AI-POWERED VOICE ANALYSIS ENABLES SCALABLE MENTAL HEALTH MONITORING

9.6 OTHER BIOMARKERS

10 DIGITAL BIOMARKERS MARKET, BY THERAPEUTIC AREA

10.1 INTRODUCTION

10.2 CARDIOVASCULAR

10.2.1 ATHEROSCLEROTIC CARDIOVASCULAR DISEASE/SECONDARY PREVENTION

10.2.1.1 Continuous risk monitoring and predictive insights in cardiovascular disease management – key driver

10.2.2 HEART FAILURE (HFREF & HFPEF)

10.2.2.1 Demand driven by advanced early detection and remote monitoring in heart failure management

10.2.3 HYPERTENSION

10.2.3.1 Transforming blood pressure assessment from episodic to continuous monitoring

10.2.4 ATRIAL FIBRILLATION/STROKE PREVENTION

10.2.4.1 Unlocking subclinical AF identification via long-duration rhythm analytics

10.2.5 PULMONARY HYPERTENSION

10.2.5.1 Advancement of functional endpoint measurement beyond traditional walk tests to boost growth

10.2.6 STRUCTURAL HEART DISEASE/INTERVENTIONAL CARDIOLOGY

10.2.6.1 Remote post-procedural surveillance in structural heart interventions to drive

segment

10.3 ONCOLOGY

10.3.1 SOLID TUMORS

10.3.1.1 BREAST CANCER

10.3.1.1.1 Segment driven by enhanced tumor characterization through AI-driven imaging and pathology analytics

10.3.1.2 LUNG CANCER

10.3.1.2.1 Enhanced immunotherapy response prediction using imaging biomarkers to boost growth

10.3.1.3 Prostate cancer

10.3.1.3.1 Segment growth propelled by reduced variability in cancer grading with quantitative digital pathology

10.3.1.4 COLORECTAL CANCER

10.3.1.4.1 Enhanced gastrointestinal oncology trials with decentralized functional endpoints – major driver

10.3.1.5 BRAIN TUMOR

10.3.1.5.1 Enhanced tumor monitoring with advanced MRI and volumetric analytics

10.3.1.6 OTHER SOLID TUMORS

10.3.1.6.1 Extension of digital biomarker utility across rare and heterogeneous tumor types to drive segment

10.3.2 HEMATOLOGIC MALIGNANCIES

10.3.2.1 LEUKEMIA

10.3.2.1.1 Enhanced MRD detection and quantification through AI-driven analytics to boost market

10.3.2.2 LYMPHOMA

10.3.2.2.1 Capturing immune response dynamics with continuous digital monitoring – key benefit

10.3.2.3 MULTIPLE MYELOMA

10.3.2.3.1 Segment growth driven by enhanced disease burden assessment with integrated imaging and pathology analytics

10.3.2.4 OTHER HEMATOLOGIC MALIGNANCIES

10.3.2.4.1 High-sensitivity endpoint generation in small patient populations to boost market

10.4 DIABETES

10.4.1 CONTINUOUS MONITORING PLATFORMS EXPANDING INTO HOLISTIC CARDIOMETABOLIC RISK PREDICTION

10.5 MENTAL HEALTH & BEHAVIORAL HEALTH

10.5.1 PASSIVE BEHAVIORAL AND VOICE DATA ENABLE SCALABLE OBJECTIVE CONDITION MONITORING

10.6 RESPIRATORY DISORDERS

10.6.1 EARLY EXACERBATION DETECTION THROUGH CONTINUOUS MONITORING REDUCES HOSPITALIZATIONS AND COSTS

10.7 LIFESTYLE & WELLNESS IMPROVEMENT

10.7.1 EXPANDING PREVENTIVE HEALTH THROUGH CONTINUOUS BEHAVIORAL DATA INSIGHTS

10.8 NEUROLOGY

10.8.1 REGULATORY VALIDATION OF DIGITAL ENDPOINTS TO ACCELERATE EARLY DETECTION AND TRIAL ADOPTION

10.9 MUSCULOSKELETAL DISORDERS/PAIN MANAGEMENT

10.9.1 EMPLOYER-BACKED DIGITAL CARE AND MOTION TRACKING TO DRIVE SCALABLE REHABILITATION SOLUTIONS

10.10 WOMEN'S HEALTH & REPRODUCTIVE HEALTH

10.10.1 ADDRESSING UNMET NEEDS THROUGH DATA-DRIVEN WOMEN'S HEALTH INSIGHTS

10.11 OTHER DISEASES

10.11.1 EXPANDING USE CASES TO DRIVE ADOPTION ACROSS CHRONIC AND UNDERSERVED CONDITIONS

11 DIGITAL BIOMARKERS MARKET, BY APPLICATION

11.1 INTRODUCTION

11.2 CLINICAL RESEARCH

11.2.1 PHASE II

11.2.1.1 Critical role in early-stage validation and risk reduction in clinical development

11.2.2 PHASE III

11.2.2.1 Regulatory-grade endpoint validation drives high-stakes clinical trial adoption

11.2.3 PHASE IV

11.2.3.1 Real-world evidence demand drives scalable continuous monitoring and reimbursement adoption

11.3 CLINICAL CARE

11.3.1 RISING CHRONIC DISEASE BURDEN DRIVING SHIFT TO CONTINUOUS PROACTIVE CARE

12 DIGITAL BIOMARKER MARKET, BY END USER

12.1 INTRODUCTION

12.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES

12.2.1 CLINICAL TRIAL DRIVEN EFFICIENCY THROUGH HIGH-IMPACT DIGITAL ENDPOINTS

12.3 CONTRACT RESEARCH ORGANIZATIONS

12.3.1 END-TO-END DIGITAL TRIAL EXECUTION ENABLED THROUGH ADVANCED ANALYTICS

12.4 HOSPITALS & SPECIALTY CLINICS

12.4.1 ENHANCED CLINICAL OUTCOMES WITH REAL-TIME, DATA-DRIVEN CARE DELIVERY

12.5 OTHER END USERS

12.5.1 PUBLIC FUNDING AND REAL-WORLD DATA INITIATIVES ACCELERATE ECOSYSTEM-WIDE ADOPTION

13 DIGITAL BIOMARKERS MARKET, BY REGION

13.1 INTRODUCTION

13.2 NORTH AMERICA

13.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA

13.2.2 US

13.2.2.1 Regulatory advancements and pharma-tech convergence drive market growth

13.2.3 CANADA

13.2.3.1 Increasing integration of AI-driven screening and remote monitoring to drive market

13.3 EUROPE

13.3.1 MACROECONOMIC OUTLOOK FOR EUROPE

13.3.2 GERMANY

13.3.2.1 Strong clinical trial ecosystem and progressive digital health regulation to drive market

13.3.3 FRANCE

13.3.3.1 Strong clinical trial base and evidence-driven regulatory pathways to drive market

13.3.4 UK

13.3.4.1 Strong NHS data infrastructure and push for data-enabled clinical trials to drive market

13.3.5 ITALY

13.3.5.1 Strong clinical research activity and oncology-driven demand to shape market growth

13.3.6 SPAIN

13.3.6.1 Strong clinical trial leadership and high domestic research concentration to

drive market

13.3.7 REST OF EUROPE

13.4 LATIN AMERICA

13.4.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA

13.4.2 BRAZIL

13.4.2.1 Expanding digital health ecosystem and regulatory reforms to drive digital biomarkers adoption

13.4.3 MEXICO

13.4.3.1 Growing clinical trial participation and digital transformation to drive digital biomarkers adoption

13.4.4 REST OF LATIN AMERICA

13.5 ASIA PACIFIC

13.5.1 ASIA PACIFIC: CLINICAL TRIAL INITIATIONS IN 2014 AND 2024

13.5.2 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC

13.5.3 CHINA

13.5.3.1 Expanding clinical trial leadership and advancing digital health ecosystem to drive market

13.5.4 JAPAN

13.5.4.1 Declining clinical trial activity despite strong legacy position to impact market

13.5.5 INDIA

13.5.5.1 Rapid clinical trial growth, cost advantages, and regulatory reforms to drive market

13.5.6 AUSTRALIA

13.5.6.1 Strong early-phase trial capabilities and advanced research infrastructure to drive market

13.5.7 SOUTH KOREA

13.5.7.1 Steady clinical trial growth and strong innovation ecosystem to drive market

13.5.8 REST OF ASIA PACIFIC

13.6 MIDDLE EAST & AFRICA

13.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA

13.6.2 GCC COUNTRIES

13.6.2.1 Strong digital health transformation and growing clinical research activity to drive adoption

13.6.3 SAUDI ARABIA

13.6.3.1 Expanding clinical research activity and government-led initiatives to drive market

13.6.4 UAE

13.6.4.1 Advancing digital health innovation and strategic collaborations – key growth drivers

13.6.5 OTHER GCC COUNTRIES

13.6.5.1 Regulatory initiatives, national health visions, and digital health infrastructure boost market growth

13.6.6 SOUTH AFRICA

13.6.6.1 Leading clinical research hub in Africa with strong infrastructure

13.6.7 REST OF MIDDLE EAST & AFRICA

14 COMPETITIVE LANDSCAPE

14.1 OVERVIEW

14.2 KEY PLAYER STRATEGIES/RIGHT TO WIN

14.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN DIGITAL BIOMARKERS MARKET

14.3 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS

14.4 MARKET SHARE ANALYSIS, 2025

14.5 BRAND COMPARISON

14.6 COMPANY VALUATION & FINANCIAL METRICS

14.6.1 FINANCIAL METRICS

14.6.2 COMPANY VALUATION

14.7 COMPANY EVALUATION MATRIX

14.7.1 STARS

14.7.2 EMERGING LEADERS

14.7.3 PERVASIVE PLAYERS

14.7.4 PARTICIPANTS

14.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025

14.7.5.1 Company footprint

14.7.5.2 Region footprint

14.7.5.3 Type footprint

14.7.5.4 Therapeutic area footprint

14.7.5.5 Application footprint

14.7.5.6 End user footprint

14.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025

14.8.1 PROGRESSIVE COMPANIES

14.8.2 RESPONSIVE COMPANIES

14.8.3 DYNAMIC COMPANIES

14.8.4 STARTING BLOCKS

14.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024

14.8.5.1 Detailed list of key startups/SMEs

14.8.5.2 Competitive benchmarking of startups/SMEs

14.9 COMPETITIVE SCENARIO

14.9.1 PRODUCT/SERVICE LAUNCHES & APPROVALS

14.9.2 DEALS

14.9.3 OTHER DEVELOPMENTS

15 COMPANY PROFILES

15.1 KEY PLAYERS

15.1.1 IXICO PLC

15.1.1.1 Business overview

15.1.1.2 Products offered

15.1.1.3 Recent developments

15.1.1.3.1 Product launches/approvals

15.1.1.3.2 Deals

15.1.1.4 MnM view

15.1.1.4.1 Key strengths

15.1.1.4.2 Strategic choices

15.1.1.4.3 Weaknesses and competitive threats

15.1.2 AMETRIS, LLC

15.1.2.1 Business overview

15.1.2.2 Products Offered

15.1.2.3 Recent developments

15.1.2.3.1 Product launches/enhancements

15.1.2.3.2 Deals

15.1.2.4 MnM view

15.1.2.4.1 Key strengths

15.1.2.4.2 Strategic choices

15.1.2.4.3 Weaknesses and competitive threats

15.1.3 EMPATICA INC.

15.1.3.1 Business overview

15.1.3.2 Products/Solutions offered

15.1.3.3 Recent developments

15.1.3.3.1 Product launches/approvals

15.1.3.3.2 Deals

15.1.3.4 MnM view

15.1.3.4.1 Key strengths

15.1.3.4.2 Strategic choices

15.1.3.4.3 Weaknesses and competitive threats

15.1.4 ALIVECOR, INC.

- 15.1.4.1 Business overview
- 15.1.4.2 Products offered
- 15.1.4.3 Recent developments
 - 15.1.4.3.1 Product launches/approvals
 - 15.1.4.3.2 Deals
- 15.1.4.4 MnM view
 - 15.1.4.4.1 Key strengths
 - 15.1.4.4.2 Strategic choices
 - 15.1.4.4.3 Weaknesses and competitive threats
- 15.1.5 CONNEQT HEALTH
 - 15.1.5.1 Business overview
 - 15.1.5.2 Products offered
 - 15.1.5.3 Recent developments
 - 15.1.5.3.1 Product enhancements/approvals
 - 15.1.5.4 MnM view
 - 15.1.5.4.1 Key strengths
 - 15.1.5.4.2 Strategic choices
 - 15.1.5.4.3 Weaknesses and competitive threats
- 15.1.6 VIVOSENSE
 - 15.1.6.1 Business overview
 - 15.1.6.2 Products offered
 - 15.1.6.2.1 Other developments
- 15.1.7 BIOSENSICS
 - 15.1.7.1 Business overview
 - 15.1.7.2 Products offered
 - 15.1.7.3 Recent developments
 - 15.1.7.3.1 Product launches/approvals
 - 15.1.7.3.2 Deals
- 15.1.8 LUNIT INC.
 - 15.1.8.1 Business overview
 - 15.1.8.2 Products offered
 - 15.1.8.3 Recent developments
 - 15.1.8.3.1 Product launches/approvals
 - 15.1.8.3.2 Deals
- 15.1.9 AKILI, INC.
 - 15.1.9.1 Business overview
 - 15.1.9.2 Products offered
 - 15.1.9.3 Recent developments
 - 15.1.9.3.1 Deals

15.1.10 QUIBIM

15.1.10.1 Business overview

15.1.10.2 Products offered

15.1.10.3 Recent developments

15.1.10.3.1 Product launches/approvals/enhancements

15.1.10.3.2 Deals

15.1.11 CLARIO

15.1.11.1 Business overview

15.1.11.2 Products offered

15.1.11.3 Recent developments

15.1.11.3.1 Deals

15.1.12 PROSCIA INC.

15.1.12.1 Business overview

15.1.12.2 Products offered

15.1.12.3 Recent developments

15.1.12.3.1 Product launches/approvals

15.1.12.3.2 Deals

15.1.13 KONEKSA HEALTH

15.1.13.1 Business overview

15.1.13.2 Products offered

15.1.13.3 Recent developments

15.1.13.3.1 Product launches

15.1.13.3.2 Deals

15.1.14 LINUS HEALTH

15.1.14.1 Business overview

15.1.14.2 Products offered

15.1.14.3 Recent developments

15.1.14.3.1 Product launches/approvals

15.1.14.3.2 Deals

15.2 OTHER PLAYERS**15.2.1 SONDE HEALTH, INC.****15.2.2 ALTOIDA****15.2.3 IMVARIA INC.****15.2.4 CUMULUS NEUROSCIENCE LIMITED****15.2.5 DELVE HEALTH****15.2.6 FEEL THERAPEUTICS****15.2.7 NANOWEAR INC.****15.2.8 EXOSYSTEMS****15.2.9 CARDIOSIGNAL**

15.2.10 IMAGENE AI LTD.

15.2.11 NEUROTRACK TECHNOLOGIES, INC.

16 RESEARCH METHODOLOGY

16.1 RESEARCH APPROACH

16.1.1 SECONDARY RESEARCH

16.1.1.1 Key data from secondary sources

16.1.2 PRIMARY RESEARCH

16.1.2.1 Primary sources

16.1.2.2 Key data from primary sources

16.1.2.3 Breakdown of primaries

16.1.2.4 Insights from primary experts

16.2 RESEARCH METHODOLOGY DESIGN

16.3 MARKET SIZE ESTIMATION

16.4 MARKET BREAKDOWN DATA TRIANGULATION

16.5 MARKET SHARE ESTIMATION

16.6 STUDY ASSUMPTIONS

16.7 RESEARCH LIMITATIONS

16.7.1 METHODOLOGY-RELATED LIMITATIONS

16.8 RISK ASSESSMENT

17 APPENDIX

17.1 DISCUSSION GUIDE

17.2 KNOWLEDGESTORE: MARKETSandMARKETS' SUBSCRIPTION PORTAL

17.3 CUSTOMIZATION OPTIONS

17.4 RELATED REPORTS

17.5 AUTHOR DETAILS

List Of Tables

LIST OF TABLES

TABLE 1 USD EXCHANGE RATES

TABLE 2 DIGITAL BIOMARKERS MARKET: PORTER'S FIVE FORCES ANALYSIS

TABLE 3 DIGITAL BIOMARKERS MARKET: ROLE IN ECOSYSTEM

TABLE 4 INDICATIVE PRICE FOR DIGITAL BIOMARKERS, BY KEY PLAYER (2025)

TABLE 5 INDICATIVE PRICE FOR DIGITAL BIOMARKERS, BY REGION (2025)

TABLE 6 CASE 1: EMPATICA – INTEGRATION OF DIGITAL BIOMARKERS INTO HIGH-ALTITUDE ENDOCRINOLOGY RESEARCH (APEX 7 HICORT STUDY)

TABLE 7 CASE 2: VIVOSENSE – DIGITAL BIOMARKERS FOR PTSD MONITORING AND ASSESSMENT

TABLE 8 CASE 3: DELVE HEALTH – IMPROVED DATA INTEGRITY IN CLINICAL TRIALS WITH DIGITAL BIOMARKERS

TABLE 9 US ADJUSTED RECIPROCAL TARIFF RATES

TABLE 10 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF TOP THREE END USERS (%)

TABLE 11 KEY BUYING CRITERIA FOR TOP THREE END USERS

TABLE 12 UNMET NEEDS IN DIGITAL BIOMARKERS MARKET

TABLE 13 END USER EXPECTATIONS IN DIGITAL BIOMARKERS MARKET

TABLE 14 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 15 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 16 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 17 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 18 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 19 REGULATORY SCENARIO IN NORTH AMERICA

TABLE 20 REGULATORY SCENARIO IN EUROPE

TABLE 21 REGULATORY SCENARIO IN ASIA PACIFIC

TABLE 22 REGULATORY SCENARIO IN LATIN AMERICA

TABLE 23 REGULATORY SCENARIO IN MIDDLE EAST & AFRICA

TABLE 24 DIGITAL BIOMARKERS MARKET: JURISDICTION ANALYSIS OF TOP APPLICANT COUNTRIES

TABLE 25 DIGITAL BIOMARKERS MARKET: LIST OF PATENTS/PATENT APPLICATIONS

TABLE 26 DIGITAL BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 27 PHYSIOLOGICAL BIOMARKERS: MAJOR PLAYERS AND OFFERINGS

TABLE 28 PHYSIOLOGICAL BIOMARKERS: DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 29 IDIOSYNCRATIC BIOMARKERS: MAJOR PLAYERS AND OFFERINGS

TABLE 30 IDIOSYNCRATIC BIOMARKERS: DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 31 COGNITIVE BIOMARKERS: MAJOR PLAYERS AND OFFERINGS

TABLE 32 COGNITIVE BIOMARKERS: DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 33 VOCAL BIOMARKERS: MAJOR PLAYERS AND OFFERINGS

TABLE 34 VOCAL BIOMARKERS: DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 35 OTHER BIOMARKERS: MAJOR PLAYERS AND OFFERINGS

TABLE 36 OTHER BIOMARKERS: DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 37 DIGITAL BIOMARKERS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)

TABLE 38 CARDIOVASCULAR: MAJOR PLAYERS AND OFFERINGS

TABLE 39 CARDIOVASCULAR: DIGITAL BIOMARKERS MARKET, BY CONDITION, 2024–2031 (USD MILLION)

TABLE 40 CARDIOVASCULAR: DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 41 ASCVD/SECONDARY PREVENTION: DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 42 HEART FAILURE (HFREF & HFPEF): DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 43 HYPERTENSION: DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 44 ATRIAL FIBRILLATION/STROKE PREVENTION: DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 45 PULMONARY HYPERTENSION: DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 46 STRUCTURAL HEART DISEASE/INTERVENTIONAL CARDIOLOGY: DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 47 ONCOLOGY: MAJOR PLAYERS AND OFFERINGS

TABLE 48 ONCOLOGY: DIGITAL BIOMARKERS MARKET, BY TUMOR TYPE, 2024–2031 (USD MILLION)

TABLE 49 ONCOLOGY: DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031

(USD MILLION)

TABLE 50 SOLID TUMORS: DIGITAL BIOMARKERS MARKET, BY TYPE, 2024–2031

(USD MILLION)

TABLE 51 SOLID TUMORS: DIGITAL BIOMARKERS MARKET, BY REGION,
2024–2031 (USD MILLION)

TABLE 52 BREAST CANCER: DIGITAL BIOMARKERS MARKET, BY REGION,
2024–2031 (USD MILLION)

TABLE 53 LUNG CANCER: DIGITAL BIOMARKERS MARKET, BY REGION,
2024–2031 (USD MILLION)

TABLE 54 PROSTATE CANCER: DIGITAL BIOMARKERS MARKET, BY REGION,
2024–2031 (USD MILLION)

TABLE 55 COLORECTAL CANCER: DIGITAL BIOMARKERS MARKET, BY REGION,
2024–2031 (USD MILLION)

TABLE 56 BRAIN TUMOR: DIGITAL BIOMARKERS MARKET, BY REGION,
2024–2031 (USD MILLION)

TABLE 57 OTHER SOLID TUMORS: DIGITAL BIOMARKERS MARKET, BY REGION,
2024–2031 (USD MILLION)

TABLE 58 HEMATOLOGIC MALIGNANCIES: DIGITAL BIOMARKERS MARKET, BY
TYPE, 2024–2031 (USD MILLION)

TABLE 59 HEMATOLOGIC MALIGNANCIES: DIGITAL BIOMARKERS MARKET, BY
REGION, 2024–2031 (USD MILLION)

TABLE 60 LEUKEMIA: DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031
(USD MILLION)

TABLE 61 LYMPHOMA: DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031
(USD MILLION)

TABLE 62 MULTIPLE MYELOMA: DIGITAL BIOMARKERS MARKET, BY REGION,
2024–2031 (USD MILLION)

TABLE 63 OTHER HEMATOLOGIC MALIGNANCIES: DIGITAL BIOMARKERS
MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 64 DIABETES: MAJOR PLAYERS AND OFFERINGS

TABLE 65 DIABETES: DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031
(USD MILLION)

TABLE 66 MENTAL HEALTH & BEHAVIORAL HEALTH: MAJOR PLAYERS AND
OFFERINGS

TABLE 67 MENTAL HEALTH & BEHAVIORAL HEALTH: DIGITAL BIOMARKERS
MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 68 RESPIRATORY DISORDERS: MAJOR PLAYERS AND OFFERINGS

TABLE 69 RESPIRATORY DISORDERS: DIGITAL BIOMARKERS MARKET, BY
REGION, 2024–2031 (USD MILLION)

TABLE 70 LIFESTYLE & WELLNESS IMPROVEMENT: MAJOR PLAYERS AND OFFERINGS

TABLE 71 LIFESTYLE & WELLNESS IMPROVEMENT: DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 72 NEUROLOGY: MAJOR PLAYERS AND OFFERINGS

TABLE 73 NEUROLOGY: DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 74 MUSCULOSKELETAL DISORDERS/PAIN MANAGEMENT: MAJOR PLAYERS AND OFFERINGS

TABLE 75 MUSCULOSKELETAL DISORDERS/PAIN MANAGEMENT: DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 76 WOMEN'S HEALTH & REPRODUCTIVE HEALTH: MAJOR PLAYERS AND OFFERINGS

TABLE 77 WOMEN'S HEALTH & REPRODUCTIVE HEALTH: DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 78 OTHER DISEASES: DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 79 DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)

TABLE 80 CLINICAL RESEARCH: DIGITAL BIOMARKERS MARKET, BY PHASE, 2024–2031 (USD MILLION)

TABLE 81 CLINICAL RESEARCH: DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 82 PHASE II CLINICAL RESEARCH: DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 83 PHASE III CLINICAL RESEARCH: DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 84 PHASE IV CLINICAL RESEARCH: DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 85 CLINICAL CARE: DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 86 DIGITAL BIOMARKER MARKET, BY END USER, 2024–2031 (USD MILLION)

TABLE 87 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES: DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 88 CONTRACT RESEARCH ORGANIZATIONS: DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 89 HOSPITALS & SPECIALTY CLINICS: DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 90 OTHER END USERS: DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 91 DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 92 NORTH AMERICA: DIGITAL BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 93 NORTH AMERICA: DIGITAL BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 94 NORTH AMERICA: DIGITAL BIOMARKERS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)

TABLE 95 NORTH AMERICA: DIGITAL BIOMARKERS MARKET FOR CARDIOVASCULAR, BY CONDITION, 2024–2031 (USD MILLION)

TABLE 96 NORTH AMERICA: DIGITAL BIOMARKERS MARKET FOR ONCOLOGY, BY TUMOR TYPE, 2024–2031 (USD MILLION)

TABLE 97 NORTH AMERICA: DIGITAL BIOMARKERS MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION)

TABLE 98 NORTH AMERICA: DIGITAL BIOMARKERS MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION)

TABLE 99 NORTH AMERICA: DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)

TABLE 100 NORTH AMERICA: DIGITAL BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY PHASE, 2024–2031 (USD MILLION)

TABLE 101 NORTH AMERICA: DIGITAL BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION)

TABLE 102 US: DIGITAL BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 103 US: DIGITAL BIOMARKERS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)

TABLE 104 US: DIGITAL BIOMARKERS MARKET FOR CARDIOVASCULAR, BY CONDITION, 2024–2031 (USD MILLION)

TABLE 105 US: DIGITAL BIOMARKERS MARKET FOR ONCOLOGY, BY TUMOR TYPE, 2024–2031 (USD MILLION)

TABLE 106 US: DIGITAL BIOMARKERS MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION)

TABLE 107 US: DIGITAL BIOMARKERS MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION)

TABLE 108 US: DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)

TABLE 109 US: DIGITAL BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY

PHASE, 2024–2031 (USD MILLION)

TABLE 110 US: DIGITAL BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION)

TABLE 111 CANADA: DIGITAL BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 112 CANADA: DIGITAL BIOMARKERS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)

TABLE 113 CANADA: DIGITAL BIOMARKERS MARKET FOR CARDIOVASCULAR, BY CONDITION, 2024–2031 (USD MILLION)

TABLE 114 CANADA: DIGITAL BIOMARKERS MARKET FOR ONCOLOGY, BY TUMOR TYPE, 2024–2031 (USD MILLION)

TABLE 115 CANADA: DIGITAL BIOMARKERS MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION)

TABLE 116 CANADA: DIGITAL BIOMARKERS MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION)

TABLE 117 CANADA: DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)

TABLE 118 CANADA: DIGITAL BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY PHASE, 2024–2031 (USD MILLION)

TABLE 119 CANADA: DIGITAL BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION)

TABLE 120 EUROPE: DIGITAL BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 121 EUROPE: DIGITAL BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 122 EUROPE: DIGITAL BIOMARKERS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)

TABLE 123 EUROPE: DIGITAL BIOMARKERS MARKET FOR CARDIOVASCULAR, BY CONDITION, 2024–2031 (USD MILLION)

TABLE 124 EUROPE: DIGITAL BIOMARKERS MARKET FOR ONCOLOGY, BY TUMOR TYPE, 2024–2031 (USD MILLION)

TABLE 125 EUROPE: DIGITAL BIOMARKERS MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION)

TABLE 126 EUROPE: DIGITAL BIOMARKERS MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION)

TABLE 127 EUROPE: DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)

TABLE 128 EUROPE: DIGITAL BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY PHASE, 2024–2031 (USD MILLION)

TABLE 129 EUROPE: DIGITAL BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION)

TABLE 130 GERMANY: DIGITAL BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 131 GERMANY: DIGITAL BIOMARKERS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)

TABLE 132 GERMANY: DIGITAL BIOMARKERS MARKET FOR CARDIOVASCULAR, BY CONDITION, 2024–2031 (USD MILLION)

TABLE 133 GERMANY: DIGITAL BIOMARKERS MARKET FOR ONCOLOGY, BY TUMOR TYPE, 2024–2031 (USD MILLION)

TABLE 134 GERMANY: DIGITAL BIOMARKERS MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION)

TABLE 135 GERMANY: DIGITAL BIOMARKERS MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION)

TABLE 136 GERMANY: DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)

TABLE 137 GERMANY: DIGITAL BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY PHASE, 2024–2031 (USD MILLION)

TABLE 138 GERMANY: DIGITAL BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION)

TABLE 139 FRANCE: DIGITAL BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 140 FRANCE: DIGITAL BIOMARKERS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)

TABLE 141 FRANCE: DIGITAL BIOMARKERS MARKET FOR CARDIOVASCULAR, BY CONDITION, 2024–2031 (USD MILLION)

TABLE 142 FRANCE: DIGITAL BIOMARKERS MARKET FOR ONCOLOGY, BY TUMOR TYPE, 2024–2031 (USD MILLION)

TABLE 143 FRANCE: DIGITAL BIOMARKERS MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION)

TABLE 144 FRANCE: DIGITAL BIOMARKERS MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION)

TABLE 145 FRANCE: DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)

TABLE 146 FRANCE: DIGITAL BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY PHASE, 2024–2031 (USD MILLION)

TABLE 147 FRANCE: DIGITAL BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION)

TABLE 148 UK: DIGITAL BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD

MILLION)

TABLE 149 UK: DIGITAL BIOMARKERS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)

TABLE 150 UK: DIGITAL BIOMARKERS MARKET FOR CARDIOVASCULAR, BY CONDITION, 2024–2031 (USD MILLION)

TABLE 151 UK: DIGITAL BIOMARKERS MARKET FOR ONCOLOGY, BY TUMOR TYPE, 2024–2031 (USD MILLION)

TABLE 152 UK: DIGITAL BIOMARKERS MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION)

TABLE 153 UK: DIGITAL BIOMARKERS MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION)

TABLE 154 UK: DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)

TABLE 155 UK: DIGITAL BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY PHASE, 2024–2031 (USD MILLION)

TABLE 156 UK: DIGITAL BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION)

TABLE 157 ITALY: DIGITAL BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 158 ITALY: DIGITAL BIOMARKERS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)

TABLE 159 ITALY: DIGITAL BIOMARKERS MARKET FOR CARDIOVASCULAR, BY CONDITION, 2024–2031 (USD MILLION)

TABLE 160 ITALY: DIGITAL BIOMARKERS MARKET FOR ONCOLOGY, BY TUMOR TYPE, 2024–2031 (USD MILLION)

TABLE 161 ITALY: DIGITAL BIOMARKERS MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION)

TABLE 162 ITALY: DIGITAL BIOMARKERS MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION)

TABLE 163 ITALY: DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)

TABLE 164 ITALY: DIGITAL BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY PHASE, 2024–2031 (USD MILLION)

TABLE 165 ITALY: DIGITAL BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION)

TABLE 166 SPAIN: DIGITAL BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 167 SPAIN: DIGITAL BIOMARKERS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)

TABLE 168 SPAIN: DIGITAL BIOMARKERS MARKET FOR CARDIOVASCULAR, BY CONDITION, 2024–2031 (USD MILLION)

TABLE 169 SPAIN: DIGITAL BIOMARKERS MARKET FOR ONCOLOGY, BY TUMOR TYPE, 2024–2031 (USD MILLION)

TABLE 170 SPAIN: DIGITAL BIOMARKERS MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION)

TABLE 171 SPAIN: DIGITAL BIOMARKERS MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION)

TABLE 172 SPAIN: DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)

TABLE 173 SPAIN: DIGITAL BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY PHASE, 2024–2031 (USD MILLION)

TABLE 174 SPAIN: DIGITAL BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION)

TABLE 175 REST OF EUROPE: DIGITAL BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 176 REST OF EUROPE: DIGITAL BIOMARKERS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)

TABLE 177 REST OF EUROPE: DIGITAL BIOMARKERS MARKET FOR CARDIOVASCULAR, BY CONDITION, 2024–2031 (USD MILLION)

TABLE 178 REST OF EUROPE: DIGITAL BIOMARKERS MARKET FOR ONCOLOGY, BY TUMOR TYPE, 2024–2031 (USD MILLION)

TABLE 179 REST OF EUROPE: DIGITAL BIOMARKERS MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION)

TABLE 180 REST OF EUROPE: DIGITAL BIOMARKERS MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION)

TABLE 181 REST OF EUROPE: DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)

TABLE 182 REST OF EUROPE: DIGITAL BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY PHASE, 2024–2031 (USD MILLION)

TABLE 183 REST OF EUROPE: DIGITAL BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION)

TABLE 184 LATIN AMERICA: DIGITAL BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 185 LATIN AMERICA: DIGITAL BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 186 LATIN AMERICA: DIGITAL BIOMARKERS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)

TABLE 187 LATIN AMERICA: DIGITAL BIOMARKERS MARKET FOR

CARDIOVASCULAR, BY CONDITION, 2024–2031 (USD MILLION)

TABLE 188 LATIN AMERICA: DIGITAL BIOMARKERS MARKET FOR ONCOLOGY, BY TUMOR TYPE, 2024–2031 (USD MILLION)

TABLE 189 LATIN AMERICA: DIGITAL BIOMARKERS MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION)

TABLE 190 LATIN AMERICA: DIGITAL BIOMARKERS MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION)

TABLE 191 LATIN AMERICA: DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)

TABLE 192 LATIN AMERICA: DIGITAL BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY PHASE, 2024–2031 (USD MILLION)

TABLE 193 LATIN AMERICA: DIGITAL BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION)

TABLE 194 BRAZIL: DIGITAL BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 195 BRAZIL: DIGITAL BIOMARKERS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)

TABLE 196 BRAZIL: DIGITAL BIOMARKERS MARKET FOR CARDIOVASCULAR, BY CONDITION, 2024–2031 (USD MILLION)

TABLE 197 BRAZIL: DIGITAL BIOMARKERS MARKET FOR ONCOLOGY, BY TUMOR TYPE, 2024–2031 (USD MILLION)

TABLE 198 BRAZIL: DIGITAL BIOMARKERS MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION)

TABLE 199 BRAZIL: DIGITAL BIOMARKERS MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION)

TABLE 200 BRAZIL: DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)

TABLE 201 BRAZIL: DIGITAL BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY PHASE, 2024–2031 (USD MILLION)

TABLE 202 BRAZIL: DIGITAL BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION)

List Of Figures

LIST OF FIGURES

FIGURE 1 DIGITAL BIOMARKERS MARKET SEGMENTATION

FIGURE 2 MARKET SCENARIO

FIGURE 3 GLOBAL DIGITAL BIOMARKERS MARKET, 2024–2031

FIGURE 4 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN DIGITAL BIOMARKERS MARKET, 2023–2026

FIGURE 5 DISRUPTIONS INFLUENCING GROWTH OF DIGITAL BIOMARKERS MARKET

FIGURE 6 HIGH-GROWTH SEGMENTS IN DIGITAL BIOMARKERS MARKET, 2026–2031

FIGURE 7 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN DIGITAL BIOMARKERS MARKET DURING FORECAST PERIOD

FIGURE 8 RISING IN CLINICAL TRIAL VOLUMES TO DRIVE GROWTH IN DIGITAL BIOMARKERS MARKET

FIGURE 9 CLINICAL RESEARCH APPLICATIONS ACCOUNTED FOR LARGEST MARKET SHARE IN NORTH AMERICA IN 2025

FIGURE 10 INDIA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD

FIGURE 11 DIGITAL BIOMARKERS MARKET: PORTER'S FIVE FORCES ANALYSIS

FIGURE 12 DIGITAL BIOMARKERS MARKET: SUPPLY CHAIN ANALYSIS

FIGURE 13 DIGITAL BIOMARKERS MARKET: ECOSYSTEM ANALYSIS

FIGURE 14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES

FIGURE 16 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS

FIGURE 17 KEY BUYING CRITERIA FOR TOP THREE END USERS

FIGURE 18 DIGITAL BIOMARKERS MARKET: PATENT PUBLICATION TRENDS, 2015–2026

FIGURE 19 DIGITAL BIOMARKERS MARKET: JURISDICTION AND TOP APPLICANT ANALYSIS

FIGURE 20 DIGITAL BIOMARKERS MARKET: TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS), JANUARY 2015–APRIL 2026

FIGURE 21 MARKET POTENTIAL OF AI/GEN AI ON DIGITAL BIOMARKERS ACROSS INDUSTRIES

FIGURE 22 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS

FIGURE 23 TRIAL PHASES WITH DIGITAL ENDPOINTS

FIGURE 24 NORTH AMERICA: DIGITAL BIOMARKERS MARKET SNAPSHOT

FIGURE 25 ASIA PACIFIC: DIGITAL BIOMARKERS MARKET SNAPSHOT
FIGURE 26 DIGITAL BIOMARKERS MARKET: REVENUE ANALYSIS OF KEY PLAYERS
FIGURE 27 DIGITAL BIOMARKERS MARKET SHARE ANALYSIS OF KEY PLAYERS (2025)
FIGURE 28 DIGITAL BIOMARKERS MARKET: BRAND COMPARATIVE ANALYSIS
FIGURE 29 EV/EBITDA OF KEY VENDORS
FIGURE 30 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 31 DIGITAL BIOMARKERS MARKET: COMPANY EVALUATION MATRIX (2025)
FIGURE 32 DIGITAL BIOMARKERS MARKET: COMPANY FOOTPRINT
FIGURE 33 DIGITAL BIOMARKERS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
FIGURE 34 IXICO PLC: COMPANY SNAPSHOT (2025)
FIGURE 35 CONNEQT HEALTH: COMPANY SNAPSHOT (2025)
FIGURE 36 LUNIT INC.: COMPANY SNAPSHOT (2025)
FIGURE 37 RESEARCH DESIGN
FIGURE 38 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
FIGURE 39 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
FIGURE 40 BOTTOM-UP APPROACH
FIGURE 41 TOP-DOWN APPROACH
FIGURE 42 CAGR PROJECTIONS BASED ON DROC ANALYSIS OF DIGITAL BIOMARKERS INDUSTRY
FIGURE 43 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
FIGURE 44 DATA TRIANGULATION METHODOLOGY

I would like to order

Product name: Digital Biomarkers Market by Type (Physiological, Vocal, Idiosyncratic), Therapy [Cardio, Onco (Lung, Breast Cancer), Mental Health, Neuro], Application [Clinical Research (Phase IV)], End User (Pharma & Biotech Companies, CROs) – Global Forecast to 2031

Product link: <https://marketpublishers.com/r/D5CD44047BA9EN.html>

Price: US\$ 4,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/D5CD44047BA9EN.html>